GNPX

Genprex, Inc.

Nasdaq· Pharmaceutical Preparations· Inc. TX· CIK 0001595248 Biotech & Drug Discovery

$1.81 +0.00 (+0.00%)

Oct 26 4:00 PM ET · prev $1.81

Market cap

$1.6M

Nano cap

Next earnings

Nov 12

in 16 days

1 year

−99.1%

from $192.50 · Oct 27

30 days

−35.6%

from $2.81

52-week range

$1.81–192.50

−99% from high · low Oct 23

Avg volume 20D

190.9K

shares / day

Short interest

🔒 Subscribers only

Insider net

−$22.14

0 buyers · 1 seller · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

Congress trades

disclosed

SecBot read MIXED 3 reports · 90 days

Balance 0 bearish · 0 bullish · 3 neutral oldest → newest, height = score

Avg score

·High conf. 2/3 ·Next Earnings date, Nov 12, 2026

Strongest NEUTRAL Genprex issued a press release highlighting peer-reviewed mouse research on the TUSC2 tumor suppressor…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

S Apr 14 1 insider sell $22.14 at $1.23
R Apr 21 Genprex announced a new Sponsored Research Agreement with MD Anderso…
R Jul 14 Genprex filed a Certificate of Amendment for a 1:22 reverse stock sp…
E Jul 15 Trading halt: Trading Halt: GNPX — T1 (News Pending)
E Jul 16 Trading halt: Halt Resumed: GNPX — trading resumed after T3 (News and Re…
X Jul 31 Short interest falls 95.8% to 36.9K
X Aug 14 Short interest jumps 69.7% to 62.6K
X Aug 31 Short interest jumps 37.2% to 85.9K

Signal stack

Where each data set points today.

InsidersBEARISH

1 insider sold $22.14.
InstitutionsMIXED

Q2 2026: 3 added (0 new), 2 trimmed or exited.
TrendDOWNTREND

42% below its 50-day average. New closing low $1.81 on Oct 26.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
GEODE CAPITAL MANAGEMENT, LLC	ADD	60,348	$31.3K
UBS Group AG	DOUBLED	4,489	$2.3K
JONES FINANCIAL COMPANIES LLLP	TRIM	1,208	$597.00
OSAIC HOLDINGS, INC.	TRIM	82	$41.00
Allworth Financial LP	DOUBLED	23	$12.00
JONES FINANCIAL COMPANIES LLLP	ADD	2,105	$3.8K
CITIGROUP INC	DOUBLED	2,039	$3.7K
UBS Group AG	NEAR_EXIT	1	$2.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action May 2024

Recent actions

Date	Firm	Action	Rating
May 17, 2024	HC Wainwright & Co. REITERATE	REITERATE	Buy
May 15, 2024	HC Wainwright & Co. REITERATE	REITERATE	Buy
Apr 4, 2024	HC Wainwright & Co. REITERATE	REITERATE	Buy
Apr 3, 2024	HC Wainwright & Co. REITERATE	REITERATE	Buy
Mar 25, 2024	HC Wainwright & Co. INITIATE	INITIATE	Buy

Insider ledger

Form 4

bought · 0 insiders

$22.14

sold · 1 insider

Date	Insider	Type	Value
Apr 14, 2026	LONGNECKER BRENT M Director	SELL	$12.30
Apr 14, 2026	LONGNECKER BRENT M Director	SELL	$9.84
Feb 27, 2026	Confer Ryan M. President, CEO and CFO	TAX W/H	$18.7K
Feb 27, 2026	Berger Mark Stanley Chief Medical Officer	TAX W/H	$14.3K

Earnings setup

Estimates

Nov 12

reports in 16 days

Period	EPS est.	Range	30D rev.	Revenue
Current Q	—	—	—	$0.00
Next Q	—	—	—	$0.00
Current FY	—	—	—	$0.00
Next FY	—	—	—	$0.00

Congressional trades

GNPX trades disclosed by members of Congress, with disclosure delay.

1 members · 1 buys / 0 sells

Date	Member	Type	Amount	Disclosed
Feb 5, 2026	Timothy Moore R· HOUSE· GENPREX INC	BUY	$1,001 - $15,000	Feb 20, 2026(15d)

Short side

FINRA· Oct 15, 2026

🔒 Subscribers only

shares short

Trading halts

Jul 15, 2026

Resumption Scheduled

Resumed

Recent activity

The latest filings, insider trades, analyst actions, press and options flow — newest first.

Oct 21, 2026 SEC

Genprex issued a press release highlighting peer-reviewed mouse research on the TUSC2 tumor suppressor gene's role in…

8-K — Impact 2/10

Aug 18, 2026 SEC

Genprex announced a development and manufacturing agreement with a U.S.-based CDMO to scale up production of its…

8-K — Impact 4/10

Aug 18, 2026 Contract

Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy

Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Stud

Aug 3, 2026 SEC

Genprex announced a collaboration with Roche Diagnostics to validate TROP2 and PTEN biomarkers for patient selection…

8-K — Impact 4/10

Jun 30, 2026 Inst.

GEODE CAPITAL MANAGEMENT, LLC — ADD

60,348 shares ($31.3K)

Jun 30, 2026 Inst.

UBS Group AG — DOUBLED

4,489 shares ($2.3K)

Apr 14, 2026 Insider

LONGNECKER BRENT M sold 10 shares

Director @ $1.23 ($12.30)

Apr 14, 2026 Insider

LONGNECKER BRENT M sold 8 shares

Director @ $1.23 ($9.84)

Catalysts

Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.

Upcoming

Nov 12, 2026

Earnings date

GNPX Q3 2026 Earnings Scheduled — 2026-11-12

Recent

Aug 18, 2026

Contract

Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy

Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials AUSTIN, Texas…

Aug 12, 2026

Earnings date

GNPX Q2 2026 Earnings Scheduled — 2026-08-12

Aug 5, 2026

Listing

Listing Status: GNPX — Normal (was Deficient)

Genprex, Inc. - Common Stock | Nasdaq Financial Status Indicator D → N

Aug 3, 2026

Contract

Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies

Collaboration Advances Biomarker-Driven Patient Selection and Precision Medicine in Oncology Validation Studies Aim to Optimize Clinical Trial…